Spotlight On
Latest in Spotlight On
Treatment with tocilizumab and steroids is standard, but new therapies are emerging
Sep 20, 2024
Until 2017, no FDA approved options existed for serious side effect of dopamine-blocking drugs
Aug 13, 2024
Clinicians need to rely on prescribing practices that minimize risk of development, says expert
Aug 13, 2024
Until 2017, no FDA approved options existed for serious side effect of dopamine-blocking drugs
Aug 13, 2024
Clinicians need to rely on prescribing practices that minimize risk of development, says expert
Aug 13, 2024
More in Spotlight On
PCPs are "perfectly situated" to identify initial thinking changes of patients, expert says
Jul 05, 2024